MorphoSys reports responses with MOR202 for MM

MorphoSys AG (Xetra:MOR; PINK:MPSYF) said MOR202, a human HuCAL antibody against CD38, produced two partial responses and two minor responses in an ongoing Phase I/IIa dose-escalation study to treat relapsed/refractory multiple myeloma. MorphoSys presented the data at the International Myeloma Workshop in Rome.

MorphoSys said a previously reported minor response progressed to a PR in a patient receiving 8 mg/kg MOR202 in combination with dexamethasone. One patient receiving 16 mg/kg MOR202 and dexamethasone had a minor response. ...